ABOUT CORNING LIFE SCIENCES
Corning Life Sciences is a global, leading manufacturer of lab tools for growing cells, bioprocess manufacturing, liquid handling, benchtop equipment, among other solutions for life sciences. Corning strives to improve efficiencies and develop innovations that enable researchers to harness the power of cells to create breakthrough discoveries in research areas like cancer, primary cells, stem cells, drug discovery, cell and gene therapy and lab automation. Learn more at www.corning.com/lifesciences.
Learn how CDMOs fill the gap between cutting-edge science and the commercial sector of cell-and-gene therapeutics by partnering with the best technology providers to maximize the manufacturing process.
Explore some automated scale-up solutions and how you can design and execute your allogeneic cell therapy seed chain from phase 1 onward.
Explore some factors to consider when making the critical decision on whether to use an open or closed system for the bioprocess manufacturing process.
While extracellular vesicles represent significant opportunity for the biologics space, researchers are still building a foundation of knowledge surrounding their biology, application, and ultimate value.
Regenerative medicine company ViaCyte Inc. explored new technologies to enable expanded scales of culturing hESCs for development of cell replacement therapies as a functional cure for Type 1 diabetes.
The Corning Ascent FBR System can ease or eliminate therapy developers’ difficult choice between adherent and suspension cell culture platforms when scaling production.
Partnership scrutiny is critical for cell and gene sponsors transitioning from pure R&D and early preclinical work into clinical-phase development.
Learn what solutions Paris University Hospitals Consortium’s core facility for cell and gene therapy is using to isolate and expand mesenchymal stromal cells.
Read how culture dispensed by a bioprinter are suitable for further molecular and protein analysis as well as downstream applications including high throughput drug screening.
We demonstrate a 12-layer cell culture vessel can be used to produce seven trillion high quality EVs from mesenchymal stem cells (MSCs).
With the combination of a viral vector platform and a fixed bed bioreactor platform, a lab is working on a curative gene therapy that could address and possibly reverse T1D's underlying mechanisms.
We review what researchers should consider when they are creating a risk-mitigating adherent culture process for cell and gene therapy scale-up.
Industry experts discuss platforms for adherent cell culture scale-up, how to trim time and costs, and how to deliver high-efficiency output across adherent applications.
Read about the ample new tools and technologies in the lab available to scientists to support those MSC workflows for improved scale and cell quality.
We demonstrate by automating the handling of multiple vessels during critical liquid handling steps, the manipulator platform simplifies fill, empty, and harvest steps for a more reproducible process.
We review the advantages, disadvantages, and scaling considerations of adeno-associated virus (AAV) and lentivirus (LV) vector gene transfer mechanisms.
We review what to consider when selecting an adherent or a suspension platform for your cell culture method to achieve the best growing conditions.
Explore the changing landscape of stem cell research and cell therapy production and read how emerging solutions have facilitated a new era of more effective and efficient workflows.
Read how with more efficient and consistent production methods, researchers will be able to maximize the full potential of EVs for research and therapeutic application.
Dr. Carolyn Wrightson shares some of the valuable lessons and considerations she and her team learned about stem cell therapy scale-up and optimization.
Corning Life Sciences
836 North Street
Tewksbury, MA 01876
Contact: Nicole Athanas
- Automate To Accelerate: Meet The Corning® Matribot® Bioprinter
- Viral Vector Manufacturing And Cell Harvesting From A Single Bioreactor?
- Stack Facts: Scaling Up From Research To Clinical Applications
- Corning® Fetal Bovine Serum
- Corning® CellSTACK® Culture Chamber PEIpro® Transfection Protocol
- Guidelines For Use Of Erlenmeyer Flasks
- Corning® 5L Erlenmeyer Aseptic Transfer Cap For Transfer By Vacuum Or Positive Pressure
- Calculating Cellular Mass Balance After Corning® X-SERIES® Processing
- Corning® CellCube® Culture System Cell Expansion
- Audience Q&A
- Design and Execution of Comparability Studies
- Donor-to-Donor Variability
- How The Process Influences the Product
- Increased Comparability Burden During Clinical Trials
- Challenges Associated with Comparability for Cell-Based Products
- How To Choose Your Tools For 3D Cell Culture
- Teach Me In 10: Techniques For Harvesting Adherent Cells
- Corning® Matribot® Bioprinter: Accelerate Development And Streamline The Workflow Of 3D Models
- Do More With Corning® HYPERStack® Cell Culture Vessels
- Discover How Corning Products Help MEARY Center Paris Advance Personalized Medicine
- Map Your Scale-up Strategy With A Corning Field Applications Scientist
- Map Your Scale-up Strategy With A Corning Field Applications Specialist
- Accelerate Adherent Scale Up With The Corning® Ascent™ Fixed Bed Bioreactor System
- Scaling Up With Corning's HYPER technology